logo
← ETF screener

Simplify Propel Opportunities ETF

SURI

Simplify

Simplify Propel Opportunities ETF (SURI) on the Akinda fund screen (AAOIFI-derived): Not halal. Coverage 88.72%. Below: the fund under all five rulebooks, its facts and every holding with its own verdict.

Akinda fund screen

Akinda fund screen (AAOIFI-derived)Not halalCoverage: 88.72%
  • Halal 4.45%
  • Doubtful 0.00%
  • Not halal 84.27%
  • Not rated 11.28%

The bar is scaled to fit; the figures are as reported, and the buckets do not always total 100%.

Coverage is the share of the fund's weight we hold a usable verdict for. Below 95%, a fund is rated only when the weight we can see already breaches the 5% limit; otherwise it is not rated by this method.

Fund facts

Issuer
Simplify
Venue (where it trades)
United States
Domicile (where it is registered)
United States
Reporting currency
USD
Expense ratio
2.84%
AUM
71.75M USD
Holdings
24 (23 screened)
Basket as of (provider)
28 Oct 2026
Basket fetched by Akinda
28 Oct 2026
Verdict updated
3 Nov 2026

Venue is where a fund trades; domicile is where it is registered. London-listed funds are domiciled in Ireland or Luxembourg, so use Venue for UK ETFs.

Five rulebooks

RulebookVerdictHalalNot halalSplit (0–100%)
Akinda fund screen (AAOIFI)Not halal4.45%84.27%
DJIMNot halal8.94%79.78%
FTSENot halal0.00%88.72%
MSCINot halal0.00%88.72%
S&PNot halal10.66%77.48%

Every bar uses the same 0–100% scale. Index rulebooks report only halal and not-halal weight; uncoloured weight is weight that rulebook does not classify. Coverage is published for the Akinda fund screen only.

The fund screen and the four index rulebooks answer different questions, so they are expected to disagree. A fund can be doubtful on our fund screen and halal under S&P; both are correct.

Holdings

1–24 of 24 holdings, largest first · basket as of 28 Oct 2026
No.HoldingWeightAkinda (AAOIFI)DJIMFTSEMSCIS&P
1
ACHVACHIEVE LIFE SCIENCES INC USD 0.001
8.72%Not halalNot halalNot halalNot halalNot halal
2
PAGPPLAINS GP HLDGS L P
48.87%Not halalNot halalNot halalNot halalNot halal
3
DCTHDELCATH SYS INC USD 0.01
4.49%Not halalHalalNot halalNot halalHalal
4
MISTMILESTONE PHARMACEUTICALS INC NPV
3.13%Not halalNot halalNot halalNot halalNot halal
5
COLLCOLLEGIUM PHARMACEUTICAL USD 0.001
2.91%Not halalNot halalNot halalNot halalNot halal
6
CORTCORCEPT THERAPEUTICS INC USD 0.001
2.43%HalalHalalNot halalNot halalHalal
7
PHATPHATHOM PHARMACEUTICALS USD 0.0001
2.02%HalalHalalNot halalNot halalHalal
8
OBIOORCHESTRA BIOMED HLDGS I USD 0.0001
1.71%Not halalNot halalNot halalNot halalHalal
9
ABEOABEONA THERAPEUTICS INC USD 0.01
1.66%Not halalNot halalNot halalNot halalNot halal
10
IVAINVENTIVA SA NPV ADR
1.56%Not halalNot halalNot halalNot halalNot halal
11
AQSTAQUESTIVE THERAPEUTICS IN USD 0.001
1.53%Not halalNot halalNot halalNot halalNot halal
12
CMPSCOMPASS PATHWAYS PLC USD 0.008 ADR
1.44%Not halalNot halalNot halalNot halalNot halal
13
KYTXKYVERNA THERAPEUTICS IN USD 0.00001
1.39%Not halalNot halalNot halalNot halalNot halal
14
CABACABALETTA BIO INC USD 0.00001
1.09%Not halalNot halalNot halalNot halalNot halal
15
PROKPROKIDNEY CORP DEL USD 0.0001
0.99%Not halalNot halalNot halalNot halalNot halal
16
CLDXCELLDEX THERAPEUTICS INC USD 0.001
0.88%Not halalNot halalNot halalNot halalNot halal
17
LONALEONABIO INC USD 0.0001
0.76%Not halalNot halalNot halalNot halalNot halal
18
OCULOCULAR THERAPEUTIX INC USD 0.0001
0.74%Not halalNot halalNot halalNot halalNot halal
19
PALIPALISADE BIO INC USD 0.01
0.70%Not halalNot halalNot halalNot halalNot halal
20
IRDOPUS GENETICS INC USD 0.0001
0.58%Not halalNot halalNot halalNot halalNot rated
21
SABSSAB BIOTHERAPEUTICS INC USD 0.0001
0.43%Not halalNot halalNot halalNot halalNot halal
22
CRVSCORVUS PHARMACEUTICALS I USD 0.0001
0.36%Not halalNot halalNot halalNot halalNot halal
23
IMUXIMMUNIC INC USD 0.0001
0.32%Not halalNot halalNot halalNot halalNot halal
24
EIGRQEIGER BIOPHARMACEUTICALS USD 0.0001
0.00%Not ratedNot ratedNot ratedNot ratedNot rated

Not rated means we hold no usable verdict for that company; it is never treated as compliant.

How Akinda screens funds and stocks